Could a drug cocktail shrink sarcomas before surgery?

NCT ID NCT05167994

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving a drug called anlotinib (which cuts off tumor blood supply) along with immunotherapy (penpulimab) and radiation before surgery can improve outcomes for people with soft tissue sarcoma in the arms, legs, or trunk. The study will enroll 30 adults and focus on safety, wound complications, and quality of life. It is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anlotinib hydrochloride (a drug that blocks blood vessel growth) and penpulimab (an immunotherapy drug)
What this could lead to: If successful, this combination could improve tumor shrinkage before surgery and reduce wound complications for people with soft tissue sarcoma.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply widely. The combination may increase side effects like wound healing problems or toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANLOTINIB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANLOTINIB EXTREMITY INTENSITY-MODULATED RADIOTHERAPY MAJOR WOUND COMPLICATIONS SARCOMA,SOFT TISSUE TRUNK

Contacts and locations

Locations

Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.